Xie, Peng
Shao, Tiannan
Long, Yujun
Xie, Weiwei
Liu, Yangjun
Yang, Ye
Huang, Yuyan
Wu, Renrong
Deng, Qijian
Tang, Hui
Funding for this research was provided by:
Key Research and Development Program of Hunan Province of China (2022SK2043)
National Natural Science Foundation of China (82271545, 82101578)
Article History
Received: 5 March 2024
Accepted: 12 July 2024
First Online: 24 July 2024
Declarations
:
: The study is a part of the project, “Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients”, which has been approved by the Medical Ethics Committee of the Second Xiangya Hospital of Central South University (ref: 2016S035). The conduction of this study followed the Declaration of Helsinki. All participants provided written consent.
: Not applicable.
: The authors declare no competing interests.